AI and ML are revolutionizing oncology, driving growth in companies like BioXcel and Tempus.

From Nasdaq: 2025-03-19 14:13:00

Artificial Intelligence (AI) and Machine Learning (ML) are transforming precision oncology by analyzing data, detecting cancer cells, and enhancing patient outcomes. The National Institutes of Health (NIH) are exploring the PRIMED-AI initiative to link AI/ML for disease diagnosis and treatment, predicting patient responses to therapies.

The global AI in oncology market is expected to reach $11.52 billion by 2030, attracting investor interest in companies like BioXcel Therapeutics (BTAI), Tempus AI (TEM), and Quest Diagnostics (DGX). NVIDIA, Palantir, Google’s DeepMind, IBM Watson Health, and Microsoft are leading the charge in AI-driven healthcare innovations.

BioXcel expedites drug discovery with its AI platform, Tempus AI leverages AI for precision medicine, and Quest Diagnostics uses AI in cancer diagnostics. These companies are attracting investors with strong growth projections and innovative technologies. The AI revolution in healthcare is reshaping cancer diagnosis and treatment, offering long-term investment opportunities.



Read more at Nasdaq: Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight